New tests launched in April


New Tests

In April 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The new tests that launched in April 2022 by Mayo Clinic Laboratories:

ASYN | Alpha Synuclein Immunostain, Technical Component Only

This test is useful for the identification of alpha synuclein in neurogenerative disorders.

CITR | Citrate Excretion, 24 Hour, Urine

This test is intended for diagnosing risk factors for patients with calcium kidney stones and monitoring results of therapy in patients with calcium stones or renal tubular acidosis.

CITRA | Citrate Excretion, Random, Urine

This test is useful for diagnosing risk factors for patients with calcium kidney stones using random urine specimens and monitoring results of therapy in patients with calcium stones or renal tubular acidosis.

FCSC | Synthetic Cannabinoid Metabolites Screen, Expanded, Urine

This test is a cannabinoid screen via urine specimen by way of high performance liquid chromatography/tandem mass spectrometry.

FHPP2 | Hypersensitivity Pneumonitis FEIA Panel II

This test is useful for detecting antibody levels in patients who may have been immunologically sensitized to the pneumonitis antigen.

FRDIG | Digoxin, Free, Serum

This test is intended for evaluating recrudescent (breakthrough) digoxin toxicity in renal-failure patients and assessing the need for antidigoxin Fab to be administered.

Additionally, this test is useful for deciding when to reintroduce digoxin therapy and monitoring patients with possible digoxin-like immunoreactive factors (DLIFs).

FSARM | Immuno-CRON (+) SARS-CoV-2 (Ancestral & Omicron) Neutralizing Antibody Test

This test is intended for the measurement of specific neutralizing antibodies capable of inhibiting ancestral SARS-CoV-2 and SARS-CoV-2 Omicron variant.

FSARO | Immuno-CRON SARS-CoV-2 Omicron Neutralizing Antibody Test

This test is useful for the measurement of specific neutralizing antibodies capable of inhibiting SARS-CoV-2 Omicron variant.

KRASW | KRAS Somatic Mutation Analysis, Peritoneal Fluid

This test is intended for detecting molecular markers associated with response or resistance to specific cancer.

NFLC | Neurofilament Light Chain, Plasma

This test is useful for assessing neuronal damage related to various neurodegenerative diseases.

NSE | Neuron-Specific Enolase, Serum

This test is useful as a follow-up marker in patients with neuron-specific enolase-secreting tumors of any type, as well as an auxiliary test in the diagnosis of small cell carcinoma and the diagnosis of carcinoids, islet cell tumors, and neuroblastomas.

This test is useful as an auxiliary tool in the assessment of comatose patients.

NSESF | Neuron-Specific Enolase (NSE), Spinal Fluid

This test is useful as an auxiliary test in the diagnosis of Creutzfeldt-Jakob disease, as well as in the diagnosis of small cell lunch carcinoma metastasis to central nervous system or leptomeninges.

SCOVH | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA, Varies

Diagnosis of coronavirus disease 2019 (COVID-19) illness due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

VITB3 | Vitamin B3 and Metabolites, Plasma

This test is useful for assisting in the diagnosis of suspected vitamin B3 deficiency or toxicity and may be useful in determining response to therapy.

In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:

Meghann Southwick (@meghannsouthwick)

Meghann Southwick

Meghann Southwick is a marketing specialist for Mayo Clinic Laboratories. She has worked at Mayo Clinic since 2021.